×
About 9,996 results

ALLMedicine™ Myasthenia Gravis Center

Research & Reviews  4,771 results

Outcomes of juvenile myasthenia gravis: a comparison of robotic thymectomy with medicat...
https://doi.org/10.1016/j.athoracsur.2020.12.045
The Annals of Thoracic Surgery; Li Z, Li F et. al.

Jan 22nd, 2021 - The study aims to compare the clinical outcomes of patients with juvenile myasthenia gravis (JMG) who underwent robotic thymectomy with that of those who only received medication therapy. We retrospectively reviewed patients who visited our instit...

Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report.
https://doi.org/10.12659/AJCR.928419
The American Journal of Case Reports; Payus AO, Leow Wen Hsiang J et. al.

Jan 20th, 2021 - BACKGROUND Myasthenic crisis is a condition characterized by the sudden onset of myasthenic weakness involving the respiratory muscles and requires ventilatory support to prevent death. This is a case report of respiratory failure in a 43-year-old...

Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis With Peripheral Ner...
https://doi.org/10.1097/WNF.0000000000000432
Clinical Neuropharmacology; Yang L

Jan 20th, 2021 - Administration of acetylcholinesterase inhibitors can bring about peripheral nerve hyperexcitability symptom in muscle-specific tyrosine kinase antibody positive myasthenia gravis, but the changes in electromyography before and after drug withdraw...

Physical training and exercise in myasthenia gravis.
https://doi.org/10.1016/j.nmd.2020.12.004
Neuromuscular Disorders : NMD; Gilhus NE

Jan 19th, 2021 - Myasthenia gravis is characterized by muscle weakness and fatigue. As sustained muscle use increases the weakness, the value of physical training programs has previously been questioned. This is a review to clarify the safety and usefulness of sys...

Peripheral blood hsa-circRNA5333-4: A novel biomarker for myasthenia gravis.
https://doi.org/10.1016/j.clim.2021.108676
Clinical Immunology (Orlando, Fla.); Lv J, Ren L et. al.

Jan 19th, 2021 - In this study, the potential of specific Circular RNAs (circRNAs) as novel peripheral blood biomarkers for myasthenia gravis (MG) was explored. We analyzed circRNAs in the peripheral blood of three normal controls and three MG patients using RNA m...

see more →

Guidelines  13 results

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic synd...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105910
Journal of the Neurological Sciences; , Jacob S et. al.

Apr 4th, 2020 - Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.|2020| ,Jacob S,Muppidi S,Guidon A,Guptill J,|complications,drug therapy,epidemiology,therapeutic use,therapeutic use,t...

The Association of British Neurologists' myasthenia gravis guidelines.
https://doi.org/10.1111/nyas.13503
Annals of the New York Academy of Sciences; Sussman J, Farrugia ME et. al.

Nov 9th, 2017 - Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction for which many therapies were developed before the era of evidence-based medicine. Despite the basic principles of treatment being well known, patients continue to recei...

International consensus guidance for management of myasthenia gravis: Executive summary.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114
Neurology Sanders DB, Wolfe GI et. al.

Jun 30th, 2016 - To develop formal consensus-based guidance for the management of myasthenia gravis (MG). In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international expe...

Guidelines for treatment of autoimmune neuromuscular transmission disorders.
https://doi.org/10.1111/j.1468-1331.2010.03019.x
European Journal of Neurology; Skeie GO, Apostolski S et. al.

Apr 20th, 2010 - Important progress has been made in our understanding of the autoimmune neuromuscular transmission (NMT) disorders; myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS) and neuromyotonia (Isaacs' syndrome). To prepare consensus guideli...

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological ...
https://doi.org/10.1111/j.1468-1331.2008.02246.x
European Journal of Neurology; Elovaara I, Apostolski S et. al.

Sep 17th, 2008 - Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of a number of immune-mediated neurological diseases, the consensus on its optimal use is insufficient. To define the evidence-based optimal use of IVIG in neurology, ...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  4,957 results

Outcomes of juvenile myasthenia gravis: a comparison of robotic thymectomy with medicat...
https://doi.org/10.1016/j.athoracsur.2020.12.045
The Annals of Thoracic Surgery; Li Z, Li F et. al.

Jan 22nd, 2021 - The study aims to compare the clinical outcomes of patients with juvenile myasthenia gravis (JMG) who underwent robotic thymectomy with that of those who only received medication therapy. We retrospectively reviewed patients who visited our instit...

Myasthenic Crisis as the First Presentation of Myasthenia Gravis: A Case Report.
https://doi.org/10.12659/AJCR.928419
The American Journal of Case Reports; Payus AO, Leow Wen Hsiang J et. al.

Jan 20th, 2021 - BACKGROUND Myasthenic crisis is a condition characterized by the sudden onset of myasthenic weakness involving the respiratory muscles and requires ventilatory support to prevent death. This is a case report of respiratory failure in a 43-year-old...

Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis With Peripheral Ner...
https://doi.org/10.1097/WNF.0000000000000432
Clinical Neuropharmacology; Yang L

Jan 20th, 2021 - Administration of acetylcholinesterase inhibitors can bring about peripheral nerve hyperexcitability symptom in muscle-specific tyrosine kinase antibody positive myasthenia gravis, but the changes in electromyography before and after drug withdraw...

Physical training and exercise in myasthenia gravis.
https://doi.org/10.1016/j.nmd.2020.12.004
Neuromuscular Disorders : NMD; Gilhus NE

Jan 19th, 2021 - Myasthenia gravis is characterized by muscle weakness and fatigue. As sustained muscle use increases the weakness, the value of physical training programs has previously been questioned. This is a review to clarify the safety and usefulness of sys...

Peripheral blood hsa-circRNA5333-4: A novel biomarker for myasthenia gravis.
https://doi.org/10.1016/j.clim.2021.108676
Clinical Immunology (Orlando, Fla.); Lv J, Ren L et. al.

Jan 19th, 2021 - In this study, the potential of specific Circular RNAs (circRNAs) as novel peripheral blood biomarkers for myasthenia gravis (MG) was explored. We analyzed circRNAs in the peripheral blood of three normal controls and three MG patients using RNA m...

see more →

News  179 results

Ocular Side Effects Possible With Checkpoint Inhibitors
https://www.medscape.com/viewarticle/941652

Nov 26th, 2020 - NEW YORK (Reuters Health) - People who use immune-checkpoint inhibitors have an increased risk of noninfectious uveitis and myasthenia gravis, according to a database study. Several case series have reported ocular side effects of checkpoint inhib...

COVID-19 Linked to Development of Myasthenia Gravis
https://www.staging.medscape.com/viewarticle/935985

Aug 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated with COVID-19, new research suggests. Clinicia...

COVID-19 Linked to Development of Myasthenia Gravis
https://www.medscape.com/viewarticle/935985

Aug 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Myasthenia gravis should be added to the growing list of potential neurological sequelae associated with COVID-19, new research suggests. Clinicia...

Rituximab Promising in New-Onset Myasthenia Gravis
https://www.staging.medscape.com/viewarticle/930271

May 10th, 2020 - Patients with myasthenia gravis (MG) who are treated early with the monoclonal antibody rituximab (multiple brands) achieve remission sooner than those treated later in the disease process, new research suggests. Investigators compared patients wi...

Rituximab Promising in New-Onset Myasthenia Gravis
https://www.medscape.com/viewarticle/930271

May 10th, 2020 - Patients with myasthenia gravis (MG) who are treated early with the monoclonal antibody rituximab (multiple brands) achieve remission sooner than those treated later in the disease process, new research suggests. Investigators compared patients wi...

see more →

Patient Education  21 results see all →